[{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Non-Coding RNA-Based Therapy","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Resalis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Claris Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Resalis Therapeutics \/ Claris Ventures"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RES-010","moa":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Resalis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Sunstone Life Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Resalis Therapeutics \/ Sunstone Life Science Ventures"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"RES-010","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Resalis Therapeutics \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by Resalis Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.

                          Brand Name : RES-010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : RES-010

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program RES-010, a non-coding RNA-based compound, in obesity.

                          Brand Name : RES-010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 04, 2024

                          Lead Product(s) : RES-010

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : Sunstone Life Science Ventures

                          Deal Size : $11.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).

                          Brand Name : RES-010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 22, 2023

                          Lead Product(s) : Non-Coding RNA-Based Therapy

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Claris Ventures

                          Deal Size : $10.6 million

                          Deal Type : Financing

                          blank